BC
AXSM icon

Brinker Capital’s Axsome Therapeutics AXSM Stock Holding History

Brinker Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,971
Closed -$234K – 936
2020
Q1 		$234K Buy
3,971
+82
+2% +$6.68K 0.01% 831
2019
Q4 		$402K Buy
+3,889
New +$157K 0.01% 780

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brinker Capital's AXSM Position: Q2 2020 in Review

Brinker Capital sold out of Axsome Therapeutics (AXSM) in Q2 2020, closing a stake of 3,971 shares — an estimated $234K sold.

Brinker Capital first reported a position in AXSM in Q4 2019 and held it in 2 quarters. The position peaked at $402K in Q4 2019. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2020.

  • Brinker Capital reported no remaining Axsome Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Brinker Capital sold 3,971 Axsome Therapeutics shares in Q2 2020, an estimated $234K.
  • Brinker Capital first reported a position in Axsome Therapeutics in Q4 2019 and held it in 2 quarters.
  • Brinker Capital's Axsome Therapeutics position peaked at $402K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.